Cystic Fibrosis Foundation Announces Positive Early Results For Phase 2 Clinical Trial Of VX-770 - An Oral Compound To Treat CF

The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.